Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | GPR4 | P46093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582575 | 1.00 | SRC (0.40) | SRCGPR119ESR1ESR2ADORA3 | |
| SCHEMBL30582555 | 0.89 | SRC (0.50) | SRCTGFBR1EGFRMAP4K4 | |
| SCHEMBL26108116 | 0.89 | SRC (0.50) | SRCTGFBR1EGFRMAP4K4 | |
| SCHEMBL30582517 | 0.88 | FGFR1 (0.46) | — | |
| SCHEMBL30582636 | 0.87 | HDAC2 (0.44) | SRCTGFBR1EGFRMAP4K4 | |
| SCHEMBL26108808 | 0.87 | HDAC2 (0.44) | SRCTGFBR1EGFRMAP4K4 | |
| SCHEMBL30582647 | 0.86 | SRC (0.41) | SRCTGFBR1EGFRMAP4K4 | |
| SCHEMBL26104706 | 0.86 | SRC (0.44) | SRCGPR119TGFBR1EGFR | |
| SCHEMBL30582600 | 0.86 | SRC (0.44) | SRCGPR119TGFBR1EGFR | |
| SCHEMBL26108267 | 0.86 | SRC (0.41) | SRCTGFBR1EGFRMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |